Literature DB >> 12692003

Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease.

Patrick J Gavin1, Susan E Crawford, Stanford T Shulman, Francesca L Garcia, Anne H Rowley.   

Abstract

OBJECTIVE: Coronary artery aneurysms are the major complication of Kawasaki disease (KD). Matrix metalloproteinases (MMPs) regulate remodeling and degradation of the extracellular matrix. We hypothesized that MMP-9 expression is increased in acute KD aneurysms when compared with KD nonaneurysmal arteries and arteries from control children. METHODS AND
RESULTS: MMP-2, MMP-9, tissue inhibitor of metalloproteinase (TIMP)-1, and TIMP-2 were immunolocalized in coronary arteries from children with fatal acute KD and controls. In KD coronary aneurysms, MMP-2 expression was prominent in the thickened neointima and in endothelial cells of new capillaries in areas of angiogenesis. MMP-9 was absent in control coronary arteries but was expressed in coronary artery aneurysms, nonaneurysmal coronary and noncoronary arteries, and cardiac nerves in acute KD, without an increase in TIMP-1 expression.
CONCLUSIONS: MMP-2 likely participates in remodeling of the arterial wall in acute KD, particularly in the processes of neointimal proliferation and angiogenesis. MMP-9 may play a role in the development of coronary aneurysms, but its expression is not confined to aneurysmal arteries. Systemic arterial expression of MMP-9 in acute KD, even in the absence of inflammatory changes in the vessel, suggests induction by a circulating factor, or possibly by an infectious agent with tropism for arterial tissue.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12692003     DOI: 10.1161/01.ATV.0000065385.47152.FD

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  37 in total

1.  Reduced Platelet miR-223 Induction in Kawasaki Disease Leads to Severe Coronary Artery Pathology Through a miR-223/PDGFRβ Vascular Smooth Muscle Cell Axis.

Authors:  Yuan Zhang; Yanfei Wang; Li Zhang; Luoxing Xia; Minhui Zheng; Zhi Zeng; Yingying Liu; Timur Yarovinsky; Allison C Ostriker; Xuejiao Fan; Kai Weng; Meiling Su; Ping Huang; Kathleen A Martin; John Hwa; Wai Ho Tang
Journal:  Circ Res       Date:  2020-06-29       Impact factor: 17.367

2.  Spontaneous closure of patent ductus arteriosus after an episode of Kawasaki disease: a case report.

Authors:  Ming-Chih Lin; Yun-Ching Fu; Sheng-Ling Jan
Journal:  J Med Case Rep       Date:  2012-01-25

3.  Study design and rationale to assess Doxycycline Efficacy in preventing coronary Artery Lesions in children with Kawasaki disease (DEAL trial) - A phase II clinical trial.

Authors:  Andras Bratincsak; Blair N Limm-Chan; Vivek R Nerurkar; Lauren L Ching; Venu D Reddy; Eunjung Lim; Ralph V Shohet; Marian E Melish
Journal:  Contemp Clin Trials       Date:  2017-12-05       Impact factor: 2.226

4.  Inhibition of endogenous nitric oxide in the heart enhances matrix metalloproteinase-2 release.

Authors:  Wenjie Wang; Serena Viappiani; Jolanta Sawicka; Richard Schulz
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

5.  A novel urine peptide biomarker-based algorithm for the prognosis of necrotising enterocolitis in human infants.

Authors:  Karl G Sylvester; Xuefeng B Ling; G Y Liu; Zachary J Kastenberg; Jun Ji; Zhongkai Hu; Sihua Peng; Ken Lau; Fizan Abdullah; Mary L Brandt; Richard A Ehrenkranz; Mary Catherine Harris; Timothy C Lee; Joyce Simpson; Corinna Bowers; R Lawrence Moss
Journal:  Gut       Date:  2013-09-18       Impact factor: 23.059

6.  Association of the matrix metalloproteinase-3 (-439C/G) promoter polymorphism with Kawasaki disease in Korean children.

Authors:  Young Mi Hong; Hyun-Seung Jin; In Sook Park; Soo-Jong Hong
Journal:  Heart Vessels       Date:  2008-09-20       Impact factor: 2.037

Review 7.  Comparative effectiveness of intravenous immunoglobulin from different manufacturing processes on Kawasaki disease.

Authors:  Ming-Chih Lin
Journal:  World J Pediatr       Date:  2014-05-07       Impact factor: 2.764

8.  Inhibition of matrix metalloproteinase-9 activity improves coronary outcome in an animal model of Kawasaki disease.

Authors:  A C Lau; T T Duong; S Ito; G J Wilson; R S M Yeung
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

Review 9.  Kawasaki disease.

Authors:  Dong Soo Kim
Journal:  Yonsei Med J       Date:  2006-12-31       Impact factor: 2.759

10.  Promoter polymorphism (rs3755724, -55C/T) of tissue inhibitor of metalloproteinase 4 (TIMP4) as a risk factor for Kawasaki disease with coronary artery lesions in a Korean population.

Authors:  Ju Yeon Ban; Kyung Leem Yoon; Su Kang Kim; Sungwook Kang; Joo-Ho Chung
Journal:  Pediatr Cardiol       Date:  2008-12-02       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.